Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Nonmelanoma skin cancer, primarily comprising basal cell carcinoma and cutaneous squamous cell carcinoma, represents one of the most common malignancies worldwide and a growing public health concern. According to Mingyue Wang et al., 2024, estimates, nonmelanoma skin cancers were the fifth most common cancer globally, with approximately 1,234,533 new cases and around 69,416 deaths reported worldwide in that year. Its prevalence continues to rise, particularly among aging populations and regions with high ultraviolet exposure, contributing to a substantial healthcare burden despite relatively low mortality. The nonmelanoma skin cancer pipeline analysis by Expert Market Research highlights continued innovation across emerging therapies for nonmelanoma skin cancer aimed at improving long-term disease control.
Major companies involved in the nonmelanoma skin cancer pipeline analysis include Phio Pharmaceuticals Inc., Onchilles Pharma Inc., and others.
Leading drugs currently in the pipeline include Cemiplimab, AZD6750, RP1, and others.
The pipeline is driven by the rising incidence of advanced basal and squamous cell carcinomas, increasing adoption of immunotherapies such as cemiplimab, and innovations in early-stage nonmelanoma cancer treatments.
The Nonmelanoma Skin Cancer Pipeline Analysis Report by Expert Market Research gives comprehensive insights into nonmelanoma skin cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for nonmelanoma skin cancer. The nonmelanoma skin cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The nonmelanoma skin cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with nonmelanoma skin cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to nonmelanoma skin cancer.

Read more about this report - Request a Free Sample
Nonmelanoma skin cancer is a group of malignancies, primarily basal cell carcinoma and squamous cell carcinoma, arising from abnormal growth of skin cells due to prolonged ultraviolet radiation exposure. Genetic mutations, environmental factors, and immune suppression contribute to its development, driving advancements in the novel targeted therapies for skin cancer pipeline.
Nonmelanoma skin cancer treatment includes surgical excision, radiation therapy, and evolving options such as immunotherapy pipeline for nonmelanoma skin cancer and topical treatments in skin cancer pipeline, enhancing precision, efficacy, and patient outcomes. In October 2025, FDA approved cemiplimab-rwlc (Libtayo) as an adjuvant treatment for adults with high-risk CSCC following surgery and radiotherapy, aimed at lowering the risk of disease recurrence. Emerging agents in trials seek enhanced efficacy with favorable safety profiles.
Nonmelanoma skin cancers, primarily basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are among the most frequently diagnosed cancers worldwide. According to Mingyue Wang et al., 2024, there were an estimated 1.23 million new NMSC cases and about 69,000 deaths globally in that year, ranking NMSC fifth in overall cancer incidence. Incidence is highest in high-income regions such as Australasia, North America, and Europe, driven by ultraviolet exposure and aging populations, while rates in Asia and Africa remain lower. The nonmelanoma skin cancer burden continues to increase with demographic shifts and enhanced detection.
This section of the report covers the analysis of nonmelanoma skin cancer drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The nonmelanoma skin cancer pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total nonmelanoma skin cancer clinical trials. The phase 1 covers 28%, phase 2 accounts for 44%, phase 3 covers 22% drugs, providing an in-depth analysis of each. The early phase 1 covers nearly 6% of investigational drugs for skin cancer treatment.
The drug molecule categories covered under the nonmelanoma skin cancer pipeline analysis include monoclonal antibodies, small molecules, peptides, polymers, and gene therapies. The nonmelanoma skin cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for nonmelanoma skin cancer. For instance, in December 2024, the FDA approved cosibelimab-ipdl (Unloxcyt) for adults with advanced cutaneous squamous cell carcinoma that is locally advanced or metastatic and not suitable for curative surgery or radiotherapy.
The EMR report for the nonmelanoma skin cancer pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed nonmelanoma skin cancer therapeutic assessment, analysing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in nonmelanoma skin cancer clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for nonmelanoma skin cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of nonmelanoma skin cancer drug candidates.
Cemiplimab (LIBTAYO) is being evaluated in a Phase 3 C-POST trial sponsored by Regeneron Pharmaceuticals in collaboration with Sanofi. The study examines its efficacy in preventing recurrence of high-risk cutaneous squamous cell carcinoma following surgery and radiation. Cemiplimab is a monoclonal antibody targeting the PD-1 receptor, enhancing immune-mediated tumor cell destruction, and is administered intravenously. The trial is demonstrating improved disease-free survival compared to placebo, with ongoing follow-up expected to continue through approximately 2030.
AZD6750 is a novel CD8‑guided interleukin‑2 (IL‑2) agent being evaluated for safety, pharmacokinetics and efficacy in advanced or metastatic solid tumors, including cutaneous squamous cell carcinoma (a form of nonmelanoma skin cancer). It may be administered alone or with other anticancer agents to stimulate immune‑mediated tumor control. AstraZeneca, a global biopharmaceutical leader in oncology, is conducting this Phase 1/2 clinical study as part of its broad immuno‑oncology pipeline. The study is expected to be completed by February 2029.
RP1 (vusolimogene oderparepvec) is being developed by Replimune Inc. as an oncolytic immunotherapy for nonmelanoma skin cancer. The Phase 2 IGNYTE study is evaluating safety and estimating efficacy of RP1, administered via intratumoral injection, both as monotherapy and in combination with nivolumab. The drug is engineered from a modified herpes simplex virus expressing GM-CSF and a fusogenic protein to enhance tumor cell lysis and systemic immune activation. The study is expected to be be completed by December 2028.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Nonmelanoma Skin Cancer Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for nonmelanoma skin cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into nonmelanoma skin cancer collaborations, regulatory environments, and potential growth opportunities.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.